Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Glioblastoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Glioma (540
)
Astrocytoma (74
)
Oligodendroglioma (34
)
Ependymoma (8
)
Glioma (540
)
Astrocytoma (74
)
Oligodendroglioma (34
)
Ependymoma (8
)
›
Associations
(234)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
Byvasda (bevacizumab biosimilar)
Sensitive: A1 - Approval
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
BRAF V600E
Glioblastoma
BRAF V600E
Glioblastoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
PCV
Sensitive: A2 - Guideline
PCV
Sensitive
:
A2
MGMT promoter methylation
Glioblastoma
MGMT promoter methylation
Glioblastoma
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
temozolomide
Sensitive: A2 - Guideline
temozolomide
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
lomustine
Sensitive: A2 - Guideline
lomustine
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
BRAF V600E
Glioblastoma
BRAF V600E
Glioblastoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
vemurafenib + cobimetinib
Sensitive
:
A2
NTRK3 fusion
Glioblastoma
NTRK3 fusion
Glioblastoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Glioblastoma
NTRK1 fusion
Glioblastoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Glioblastoma
NTRK3 fusion
Glioblastoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Glioblastoma
NTRK2 fusion
Glioblastoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Glioblastoma
NTRK1 fusion
Glioblastoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Glioblastoma
NTRK2 fusion
Glioblastoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
MGMT promoter methylation
Glioblastoma
MGMT promoter methylation
Glioblastoma
temozolomide + lomustine
Sensitive: A2 - Guideline
temozolomide + lomustine
Sensitive
:
A2
temozolomide + lomustine
Sensitive: A2 - Guideline
temozolomide + lomustine
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
VAL-083
Sensitive: B - Late Trials
VAL-083
Sensitive
:
B
VAL-083
Sensitive: B - Late Trials
VAL-083
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
enzastaurin
Sensitive: B - Late Trials
enzastaurin
Sensitive
:
B
enzastaurin
Sensitive: B - Late Trials
enzastaurin
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
DNX-2401
Sensitive: B - Late Trials
DNX-2401
Sensitive
:
B
DNX-2401
Sensitive: B - Late Trials
DNX-2401
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
GDC-0084
Sensitive: B - Late Trials
GDC-0084
Sensitive
:
B
GDC-0084
Sensitive: B - Late Trials
GDC-0084
Sensitive
:
B
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
GLR2007
Sensitive: B - Late Trials
GLR2007
Sensitive
:
B
GLR2007
Sensitive: B - Late Trials
GLR2007
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
VB-111
Sensitive: B - Late Trials
VB-111
Sensitive
:
B
VB-111
Sensitive: B - Late Trials
VB-111
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
CYNK-001
Sensitive: B - Late Trials
CYNK-001
Sensitive
:
B
CYNK-001
Sensitive: B - Late Trials
CYNK-001
Sensitive
:
B
No biomarker
Glioblastoma
No biomarker
Glioblastoma
VBI-1901
Sensitive: B - Late Trials
VBI-1901
Sensitive
:
B
VBI-1901
Sensitive: B - Late Trials
VBI-1901
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login